NeoPharm Announces Third Quarter 2001 Financial Results and Declares 10% Stock Dividend
...Two of the compounds under development use the Company`s tumor-targeting platform to target tumor cells and deliver the potent cytotoxic agent,...... tumor-targeting platform to target tumor cells and deliver the potent cytotoxic agent, PE38, to destroy tumors.......IL13-PE38 uses the IL13 protein to target receptors on brain and kidney tumors, while SS1-...
Nov 06 7:05 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/011106/62077_1.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines